The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis

Nephrology Dialysis Transplantation

Volumn 26, Issue 11, 2011, Pages 3458-3465

  Buchholz, Bjoern ^a   Klanke, Bernd ^a   Schley, Gunnar ^a   Bollag, Gideon ^b   Tsai, James ^b   Kroening, Sven ^a   Yoshihara, Daisuke ^c,e   Wallace, Darren P ^c   Kraenzlin, Bettina ^d   Gretz, Norbert ^d   Hirth, Peter ^b   Eckardt, Kai Uwe ^a   Bernhardt, Wanja M ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b PLEXXIKON INC   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

ERK; polycystic kidney disease; proliferation; Raf

Indexed keywords

CYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; PLX 5568; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAF PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG INHIBITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY FIBROSIS; KIDNEY POLYCYSTIC DISEASE; LIVER FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; TREATMENT RESPONSE;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CYSTS; DOGS; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; KIDNEY; LIVER CIRRHOSIS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; POLYCYSTIC KIDNEY DISEASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RATS; RATS, SPRAGUE-DAWLEY;

EID: 80155210220     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr432     Document Type: Article

References (39)

1. Arnaout MA. Molecular genetics and pathogenesis of autosomal dominant polycystic kidney disease. Annu Rev Med 2001; 52: 93-123
2. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287-1301
3. Sullivan LP, Wallace DP, Grantham JJ. Epithelial transport in polycystic kidney disease. Physiol Rev 1998; 78: 1165-1191
4. Yamaguchi T, Pelling JC, Ramaswamy NT et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 2000; 57: 1460-1471
5. Parker E, Newby LJ, Sharpe CC et al. Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system. Kidney Int 2007; 72: 157-165
6. Sweeney WE Jr, von Vigier RO, Frost P et al. Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol 2008; 19: 1331-1341
7. Yamaguchi T, Wallace DP, Magenheimer BS et al. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 2004; 279: 40419-40430
8. Yamaguchi T, Hempson SJ, Reif GA et al. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 2006; 17: 178-187
9. Pearson G, Robinson F, Beers Gibson T et al. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 2001; 22: 153-183
10. Sturgill TW, Wu J. Recent progress in characterization of protein kinase cascades for phosphorylation of ribosomal protein S6. Biochim Biophys Acta 1991; 1092: 350-357
11. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 49-139
12. Terada Y, Tomita K, Homma MK et al. Sequential activation of Raf-1 kinase, mitogen-activated protein (MAP) kinase kinase, MAP kinase, and S6 kinase by hyperosmolality in renal cells. J Biol Chem 1994; 269: 31296-31301
13. Masaki T, Foti R, Hill PA et al. Activation of the ERK pathway precedes tubular proliferation in the obstructed rat kidney. Kidney Int 2003; 63: 1256-1264
14. O'Brien LE, Tang K, Kats ES et al. ERK and MMPs sequentially regulate distinct stages of epithelial tubule development. Dev Cell 2004; 7: 21-32
15. Yamaguchi T, Nagao S, Wallace DP et al. Cyclic AMP activates BRaf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 2003; 63: 1983-1994
16. Nagao S, Yamaguchi T, Kusaka M et al. Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease. Kidney Int 2003; 63: 427-437
17. Omori S, Hida M, Fujita H et al. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol 2006; 17: 1604-1614
18. Shibazaki S, Yu Z, Nishio S et al. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum Mol Genet 2008; 17: 1505-1516
19. Bernhardt WM, Wiesener MS, Weidemann A et al. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am J Pathol 2007; 170: 830-842
20. Yamaguchi T, Reif GA, Calvet JP et al. Sorafenib inhibits cAMPdependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol 2010; 299: F944-F951
21. Buchholz B, Teschemacher B, Schley G et al. Formation of cysts by principal-like MDCK cells depends on the synergy of cAMP- and ATP-mediated fluid secretion. J Mol Med 2011; 89: 251-261
22. Tao Y, Kim J, Faubel S et al. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Proc Natl Acad Sci U S A 2005; 102: 6954-6959
23. Schafer K, Gretz N, Bader M et al. Characterization of the Han:SPRD rat model for hereditary polycystic kidney disease. Kidney Int 1994; 46: 134-152
24. Cowley BD Jr, Gudapaty S, Kraybill AL et al. Autosomal-dominant polycystic kidney disease in the rat. Kidney Int 1993; 43: 522-534
25. Torres VE. Water for ADPKD? Probably, yes. J Am Soc Nephrol 2006; 17: 2089-2091
26. Wang X, Gattone V 2nd, Harris PC et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in thePCKrat. J AmSoc Nephrol 2005; 16: 846-851
27. Wang X, Wu Y,Ward CJ et al. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 2007; 19: 102-108
28. Nagao S, Nishii K, Katsuyama M et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 2006; 17: 2220-2227
29. Gabay L, Seger R, Shilo BZ. MAP kinase in situ activation atlas during Drosophila embryogenesis. Development 1997; 124: 3535-3541
30. Kashimata M, Sayeed S, Ka A et al. The ERK-1/2 signaling pathway is involved in the stimulation of branching morphogenesis of fetal mouse submandibular glands by EGF. Dev Biol 2000; 220: 183-196
31. Hasler U, Nunes P, Bouley R et al. Acute hypertonicity alters aquaporin- 2 trafficking and induces a MAPK-dependent accumulation at the plasma membrane of renal epithelial cells. J Biol Chem 2008; 283: 26643-26661
32. Tian W, Zhang Z, Cohen DM. MAPK signaling and the kidney. Am J Physiol Renal Physiol 2000; 279: F593-F604
33. Khwaja A, Lehmann K, Marte BM et al. Phosphoinositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway. J Biol Chem 1998; 273: 18793-18801
34. Liu Z, Greco AJ, Hellman NE et al. Intracellular signaling via ERK/ MAPK completes the pathway for tubulogenic fibronectin in MDCK cells. Biochem Biophys Res Commun 2007; 353: 793-798
35. Ahrabi AK, Terryn S, Valenti G et al. PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice. J Am Soc Nephrol 2007; 18: 1740-1753
36. Torres VE, Harris PC. Mechanisms of Disease: Autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol 2006; 2: 40-55; quiz 55
37. Hassane S, Leonhard WN, van der Wal A et al. Elevated TGFbeta-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease. J Pathol 2010; 222: 21-31
38. Wang Y, Gao J, Zhang D et al. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 2010; 53: 132-144
39. WalzG,BuddeK,MannaaMet al. Everolimus in patientswith autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 830-840